The anticipation surrounding dose optimization data for Pfizer (NYSE:PFE)'s obesity treatment, danuglipron, was also mentioned as a point of interest for the first quarter. However, the analyst ...
StockStory.org on MSN23h
Pfizer (NYSE:PFE) Posts Better-Than-Expected Sales In Q4Global pharmaceutical company Pfizer (NYSE:PFE) reported Q4 CY2024 results , with sales up 21.9% year on year to $17.76 ...
Pfizer (PFE) is set to announce Q4 earnings, with analysts expecting a $0.46 profit per share and $17.26B revenue.
PFS Partners LLC lowered its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 11.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange ...
Dividend stocks have remained a focal point for investors, especially amid market volatility and the growing need for steady ...
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows ...
Drug major Pfizer Inc. (PFE), while reporting a profit in its fourth quarter, compared to prior year's loss, on Tuesday reaffirmed ...
Pfizer (NYSE:PFE – Get Free Report) had its price objective decreased by equities research analysts at Citigroup from $30.00 ...
Earnings season is in full swing in the pharma sector with major players sharing their latest results. On Tuesday (February 4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback